Optimizing antibody development through recombinant antibody services

Recombinant antibodies, as opposed to conventional hybridoma antibodies, have recently gained popularity due to their distinct benefits in high-throughput production and widespread antibody expression. The resultant recombinant antibodies, however, are identical in terms of specificity, activity, and structure to their traditional hybridoma counterparts.

Optimizing antibody development through recombinant antibody services

Image Credit: ACROBiosystems

This implies that recombinant antibodies can be highly beneficial to the wide range of applications that use antibodies, such as immunodiagnostics and other biologics-based analytical studies.

ACROBiosystems offers a versatile, one-stop solution for recombinant antibody production demands, ranging from the various requirements of research and development scientists to the substantial volumes required by pharmaceutical manufacturers.

Optimizing antibody development through recombinant antibody services

Image Credit: ACROBiosystems

To address the rising demand for custom antibody reagents used in drug discovery and preclinical research, ACROBiosystems, a leading provider in the biopharmaceutical industry, has spent the last ten years developing and optimizing its recombinant antibody technology platform.

This comprises a platform for the expression of mammalian cells that have been independently refined and is based on HEK293 and CHO cells, in addition to having experience in the large-scale manufacture of antibody reagents.

ACROBiosystems offers a one-stop solution that covers the whole antibody production workflow, from collecting antibody sequence information (or VH/VL information) to providing high-purity, low-endotoxin recombinant antibodies and offering services for switching antibody class.

ACROBiosystems offers services for producing recombinant antibodies in quantities ranging from grams to kilograms in accordance with the standard of endotoxin levels of less than 1EU/mg. They also optimize the culture and production process according to the customer’s large-scale manufacturing demands.

Recombinant Antibody Protein Services from ACROBiosystems strive to deliver prompt, high-quality recombinant antibodies that satisfy each customer’s requirements, whether it be timely delivery (as little as two weeks for the delivery of custom recombinant antibodies) or specific specifications (including yield, concentration, etc.); in keeping with its commitment to its customers to provide “Better Design, Better Quality, Better Support, and Better Customer Experience.”

ACROBiosystems aims to meet and surpass the demands of its customers.

About ACROBiosystems

ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics. The company employs an application-oriented development strategy, with a particular focus on product design, quality control, and solution-based support. Our products and services enable anyone in the field of drug development to have a more intuitive and streamlined process.

To respond to the coronavirus pandemic, ACROBiosystems has developed SARS-CoV-2 antigens specifically designed and optimized for serological test kits, including Spike-derived antigen S1, RBD, and Nucleocapsid protein. Proteins have been supplied to diagnostic companies in large quantities.

Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Mar 1, 2023 at 7:36 AM


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    ACROBiosystems. (2023, March 01). Optimizing antibody development through recombinant antibody services. News-Medical. Retrieved on June 06, 2023 from https://www.news-medical.net/whitepaper/20230301/Optimizing-antibody-development-through-recombinant-antibody-services.aspx.

  • MLA

    ACROBiosystems. "Optimizing antibody development through recombinant antibody services". News-Medical. 06 June 2023. <https://www.news-medical.net/whitepaper/20230301/Optimizing-antibody-development-through-recombinant-antibody-services.aspx>.

  • Chicago

    ACROBiosystems. "Optimizing antibody development through recombinant antibody services". News-Medical. https://www.news-medical.net/whitepaper/20230301/Optimizing-antibody-development-through-recombinant-antibody-services.aspx. (accessed June 06, 2023).

  • Harvard

    ACROBiosystems. 2023. Optimizing antibody development through recombinant antibody services. News-Medical, viewed 06 June 2023, https://www.news-medical.net/whitepaper/20230301/Optimizing-antibody-development-through-recombinant-antibody-services.aspx.

Other White Papers by this Supplier